Researchers from Children’s Hospital of Philadelphia (CHOP) believe there may be key genetic differences in the causes of attention-deficit hyperactivity disorder (ADHD) between African Americans and people of European ancestry, which may play an important part in how patients of different ethnic backgrounds respond to treatments for this condition.
The findings published online by the journal Scientific Reports suggested that structural variants of the genome play an important role in ADHD.
However, these studies focused mainly on coding regions, or regions of DNA or RNA that code for particular proteins, and were also primarily conducted in people of European ancestry.
“We felt as though prior studies of ADHD from a genomic level were not telling the entire story because of whom they were leaving out and what they were studying,” said Hakon Hakonarson, MD, Ph.D., director of the Center for Applied Genomics at the CHOP Research Institute and senior author of the study.
“Given the large number of African American individuals we have recruited into our studies, whose genomes are fundamentally more complex than those of European ancestry, we wanted to see if comparing the coding and non-coding regions of the genome in those of African American and European ancestry could help us pinpoint areas of focus for future research efforts.”
The CAG team and their collaborators generated whole-genome sequence data on 875 participants, including 205 patients diagnosed with ADHD and 670 non-ADHD controls. African Americans represented 116 of the 205 ADHD patients and 408 of the non-ADHD controls.
In addition to confirming several structural variants and target genes associated with ADHD identified in prior studies, the researchers also discovered 40 novel structural variants in patients with ADHD. They identified a cluster of structural variants in the non-coding region of pathways involved in neuronal brain function and highly relevant to the development of ADHD, including gene expression in specific ADHD phenotypes.
There was little overlap (around 6 percent) in the genes impacted by single nucleotide variants between African American and European ancestry. These differences were especially pronounced in the non-coding structural variants. These variants may also impact how patients respond to medications for ADHD.
“Whole-genome sequencing appears to be a valuable discovery tool for studying the molecular mechanisms behind ADHD,” Hakonarson said. “Additionally, the inclusion of African Americans, coupled with the study of non-coding regions of the genome, identified several structural variants that warrant further study, as they may impact both susceptibility to ADHD and how patients respond differently to therapeutic intervention.”